Phase II/III Autism Clinical Trial Shows Significant Improvements in Anxiety and Depression at 8 Weeks
Highlights:
• Important secondary endpoint from Phase II/III autism spectrum disorder (ASD) clinical trial at 8 weeks was the child’s change in Anxiety, Depression and Mood Scale (ADAMS)
• Statistically significant and clinically meaningful treatment effect in ADAMS total score shown, with children showing significant improvement from day 0 to week 8 (p<0.001)
• Approximately 40-50% of children with autism experience clinically significant levels of anxiety.1 The prevalence of depression in autistic children has been estimated at 10-20%.2
• Children receiving NTI164 showed significant clinical improvements on top of existing anxiety/depression medications (62% of NTI164 pts were on such treatments at enrolment)
- Forums
- ASX - By Stock
- NTI
- Ann: Phase II/III autism trial shows further benefits
Ann: Phase II/III autism trial shows further benefits, page-5
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.9¢ |
Change
-0.002(3.28%) |
Mkt cap ! $61.04M |
Open | High | Low | Value | Volume |
6.0¢ | 6.1¢ | 5.9¢ | $66.62K | 1.114M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 112665 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.1¢ | 70000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 112665 | 0.059 |
8 | 634075 | 0.058 |
2 | 18313 | 0.057 |
2 | 47000 | 0.056 |
3 | 103000 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.061 | 70000 | 1 |
0.062 | 193607 | 3 |
0.064 | 223386 | 2 |
0.065 | 82936 | 2 |
0.066 | 166666 | 1 |
Last trade - 15.36pm 27/09/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |